cagrisema semaglutide cagrilintide phase 3 results 2025 vs Tirzepatide: 23% Weight Loss in Trial CagriSema Outperforms Semaglutide Alone Across

It is designed as a once-weekly injectable treatment for obesity, working via amylin receptors rather than the GLP-1 pathway used by most current weight loss medications

Comparators should be condition specific (placebo saline, HA, or PRP) and descriptions of the peptide formulation, dose, route of administration, and schedule should be clearly defined

A large study of 2,000 obese adults found that participants using semaglutide combined with diet and exercise lost up to 15-20% of their body weight after 68 weeks

The choice typically comes down to your provider's preference, your absorption profile, and what your pharmacy stocks

Others offer it as an optional add-on